Andy C. Rawstron

Best Publications

• EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

  J J M van Dongen;L Lhermitte;S Böttcher;J Almeida

  1100
  Citations

• Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

  Andy C Rawstron;Fiona L Bennett;Sheila J M O'Connor;Marwan Kwok

  768
  Citations

• Diagnostic criteria for monoclonal B-cell lymphocytosis.

  Gerald E. Marti;Andy C. Rawstron;Paolo Ghia;Peter Hillmen

  557
  Citations

• Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival

  Paul Moreton;Ben Kennedy;Guy Lucas;Michael Leach

  538
  Citations

• International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia

  A C Rawstron;N Villamor;M Ritgen;S Böttcher

  493
  Citations

• Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts

  Andy C. Rawstron;Michael J. Green;Anita Kuzmicki;Ben Kennedy

  416
  Citations

• Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

  Andy C. Rawstron;Ben Kennedy;Ben Kennedy;Ben Kennedy;Paul A. S. Evans;Paul A. S. Evans;Paul A. S. Evans;Faith E. Davies;Faith E. Davies;Faith E. Davies

  394
  Citations

• Human peripheral blood B-cell compartments: A crossroad in B-cell traffic†

  M Perez-Andres;B Paiva;W G Nieto;A Caraux

  347
  Citations

• Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.

  Roger G. Owen;Robert A. Kyle;Marvin J. Stone;Andy C. Rawstron

  319
  Citations

• Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

  David Dornan;Fiona Bennett;Yvonne Chen;Mark Dennis

  317
  Citations

• Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion

  Andy C. Rawstron;Martin R. Yuille;Julie Fuller;Matthew Cullen

  314
  Citations

• Monoclonal B-cell Lymphocytosis (MBL): Biology, Natural History, and Clinical Management

  Tait D. Shanafelt;Paolo Ghia;Mark C. Lanasa;Ola Landgren

  298
  Citations

• Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage

  A C Rawstron;R G Owen;F E Davies;R J Johnson

  278
  Citations

• Highly Sensitive B Cell Analysis Predicts Response to Rituximab Therapy in Rheumatoid Arthritis

  Shouvik Dass;Andy C. Rawstron;Edward M. Vital;Karen Henshaw

  278
  Citations

• Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

  Andy C. Rawstron;Andy C. Rawstron;Andy C. Rawstron;Faith E. Davies;Faith E. Davies;Faith E. Davies;Ranjit DasGupta;Ranjit DasGupta;Ranjit DasGupta;A. John Ashcroft;A. John Ashcroft;A. John Ashcroft

  277
  Citations

• B cell biomarkers of rituximab responses in systemic lupus erythematosus.

  Edward M. Vital;Shouvik Dass;Maya H. Buch;Karen Henshaw

  273
  Citations

• Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

  Ben Kennedy;Andy Rawstron;Chris Carter;Mary Ryan

  269
  Citations

• Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

  Geoff Hale;Peppy Rebello;Lee R. Brettman;Chris Fegan

  262
  Citations

• Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL

  A C Rawstron;A C Rawstron;S Böttcher;R Letestu;N Villamor

  242
  Citations

• A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

  A. C. Rawstron;C. Fazi;A. Agathangelidis;N. Villamor

  214
  Citations